Page last updated: 2024-12-05

salicylsalicylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Salicylsalicylic acid (SSA) is a dimer of salicylic acid. It is synthesized by the reaction of salicylic acid with itself under acidic conditions. SSA has been shown to have anti-inflammatory, analgesic, and antipyretic effects, similar to salicylic acid. It is being studied for its potential use in the treatment of inflammatory diseases, such as rheumatoid arthritis and osteoarthritis. SSA is also being investigated for its potential use as a topical anti-acne agent. The compound is less irritating than salicylic acid and may be more effective at lower concentrations.'

salicylsalicylic acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5161
CHEMBL ID154111
CHEBI ID9014
SCHEMBL ID15562
MeSH IDM0062507

Synonyms (153)

Synonym
AC-18298
2-carboxyphenyl salicylate
552-94-3
disalcid
diacesal
benzoic acid, 2-carboxyphenyl ester
salical
sasapyrine
o-salicylsalicylic acid
diplosal
saloxium
sasapirin
sasapyrinum
salysal
sal ester sal
salicylic acid, bimolecular ester
nsc49171
salicylsalicylic acid
disalyl
nobacid
salsalate
disalicylic acid
salicyloylsalicylic acid
salicylic acid, salicylate
nsc-49171
salina
2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid
brn 2590908
disalicylsaeure
o-salicylcylsalicylsaeure
salsalato [inn-spanish]
nsc 49171
einecs 209-027-4
salsalatum [inn-latin]
SPECTRUM_001998
SPECTRUM5_000670
benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester
2-(2-hydroxybenzoyl)oxybenzoic acid
2-((2-hydroxybenzoyl)oxy)benzoic acid
BSPBIO_001665
salicyloxysalicylic acid
salicylic acid bimolecular ester
DB01399
sasapyrin
sasapyrine (jan)
D00428
disalcid (tn)
salsalate (usp/inn)
salflex
NCGC00096014-01
KBIO3_001165
KBIOGR_001500
KBIOSS_002572
KBIO2_002563
KBIO2_005131
KBIO2_007699
SPBIO_000845
SPECTRUM4_000940
SPECTRUM3_000173
SPECTRUM2_000693
SPECTRUM200331
NCGC00096014-02
HMS2091A05
chebi:9014 ,
CHEMBL154111
disalicyclic acid
AKOS003368478
2-salicyloyloxybenzoic acid
o-salicyloylsalicylic acid
salicylic acid 2-carboxyphenyl ester
mono-gesic
tox21_111548
dtxsid1023572 ,
cas-552-94-3
dtxcid203572
2-salicyloyloxy-benzoic acid
A830578
nsc-755823
nsc755823
pharmakon1600-00200331
cas_552-94-3
nsc_5161
bdbm85244
S4188
CCG-39652
2-(2-hydroxybenzoyloxy)benzoic acid
salsalato
salsalatum
salsalate [usan:usp:inn:ban]
unii-v9mo595c9i
v9mo595c9i ,
FT-0632376
dl-lysine acetylsalicylate impurity m [ep impurity]
carbasalate calcium impurity d [ep impurity]
salsalate [usp monograph]
salsalate [mi]
salsalate [who-dd]
salsalate [usp-rs]
salsalate [usan]
salsalate [usp impurity]
sasapyrine [jan]
salsalate [vandf]
2-[(2-hydroxybenzoyl)oxy]benzoic acid
salsalate [inn]
salsalate [mart.]
acetylsalicylic acid impurity e [ep impurity]
SCHEMBL15562
NCGC00096014-03
tox21_111548_1
CS-4891
Q-100630
2-hydroxybenzoic acid 2-carboxyphenyl ester
disalgesic
2-[(2-hydroxybenzoyl)oxy]benzoic acid #
salsalate (aspirin impurity e), pharmaceutical secondary standard; certified reference material
HY-B1245
2-salicylsalicylic acid
AB01563259_02
AB01563259_01
mfcd00020252
2-[(2-hydroxyphenyl)carbonyloxy]benzoic acid
2-carboxyphenyl salicylate, aldrichcpr
sr-05000001536
SR-05000001536-1
salsalate, united states pharmacopeia (usp) reference standard
HMS3652P07
salsalate, >=98% (hplc)
SBI-0206687.P002
SW219189-1
salicylsalicylic acid;disalicylic acid
aspirin impurity e
aspirin impurity e; 2-hydroxybenzoic acid 2-carboxyphenyl ester; salicylic acid salicylate; 2-hydroxybenzoic acid 2-carboxyphenyl ester
AS-12645
Q1320691
HMS3885J09
C75590
2-[(2-hydroxybenzoyl)oxy]benzoic acid (salicylsalicylic acid)
carboxyphenyl salicylate
disalicylsaure
salsalaterx
salsalate (usp-rs)
salsalatum (inn-latin)
salsalate (usp impurity)
acetylsalicylic acid impurity e (ep impurity)
n02ba06
salsalate (usp monograph)
o-salicylcylsalicylsaure
salsalate (usan:usp:inn:ban)
salsalate (mart.)
salsalato (inn-spanish)
HY-B1245R
CS-0694787
salsalate (standard)

Research Excerpts

Overview

Salicylsalicylic acid is a non-steroidal anti-inflammatory drug with anti-rheumatic properties. The amorphous form offers the potential for enhanced dissolution rates and improved bioavailability compared with its crystalline counterpart.

ExcerptReferenceRelevance
"Salicylsalicylic acid ("Salsalate") is a non-steroidal anti-inflammatory drug with anti-rheumatic properties, whose amorphous form offers the potential for enhanced dissolution rates and improved bioavailability compared with its crystalline counterpart. "( Amorphism and Thermal Decomposition of Salicylsalicylic Acid-A Cautionary Tale.
Aguilar, JA; Ball, AT; Coxon, CR; Kenwright, AM; Lancaster, RW; Mosely, JA; Mutton, MA, 2016
)
2.15
"Salicylsalicylic acid (salsalate) is an effective antirheumatic drug that bypasses gastric absorption and also avoids cyclooxygenase inhibition."( Gastroduodenal mucosal damage with salsalate versus aspirin: results of experimental models and endoscopic studies in humans.
Elta, GH; Scheiman, JM, 1990
)
1

Toxicity

ExcerptReferenceRelevance
"Pain is a serious adverse event which frequently accompanies hematopoietic stem cell transplantation (HSCT)."( The non-steroidal anti-inflammatory drug salsalate provides safe and effective control of mucositis-unrelated pain during autologous and allogeneic hematopoietic stem cell transplantation.
Gordon, L; Grosshans, N; Mehta, J; Rubin, H; Trifilio, S, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" The disposition of SS and SA were evaluated simultaneously using a pharmacokinetic model comprising several transit absorption steps and linear and nonlinear dual elimination pathways for SA."( Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats.
Almon, RR; Cao, Y; DuBois, DC; Jusko, WJ, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" In order to improve NO bioavailability within the vessel wall in type-1 diabetes, we investigated treatment strategies that improve eNOS phosphorylation and NO-dependent vasorelaxation."( Enhancing eNOS activity with simultaneous inhibition of IKKβ restores vascular function in Ins2(Akita+/-) type-1 diabetic mice.
de Crom, R; Habib, SL; Janardhanan, P; Krishnan, M; Mohan, S; Natarajan, M; Reddick, RL; Roman, L; van Haperen, R, 2015
)
0.42
"Salicylsalicylic acid ("Salsalate") is a non-steroidal anti-inflammatory drug with anti-rheumatic properties, whose amorphous form offers the potential for enhanced dissolution rates and improved bioavailability compared with its crystalline counterpart."( Amorphism and Thermal Decomposition of Salicylsalicylic Acid-A Cautionary Tale.
Aguilar, JA; Ball, AT; Coxon, CR; Kenwright, AM; Lancaster, RW; Mosely, JA; Mutton, MA, 2016
)
2.15
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Because the elimination of SA is impaired in patients undergoing dialysis, the interdialytic SSA dosage should be reduced."( Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis.
Brown, RS; Goldlust, MB; Griffin, VL; Harrison, LI; Rosa, RM; Shang, SF; Weinblatt, M; Williams, ME, 1986
)
0.27
" The convenient twice-daily dosage regimen makes this drug particularly suitable for chronic use."( Salsalate for arthritis: a clinical evaluation.
McPherson, TC, 1984
)
0.27
" When steady state was achieved patients were hospitalized, and blood and urine specimens were obtained during three dosing intervals and during the washout period that followed."( Availability of salicylate from salsalate and aspirin.
Cassell, S; Dromgoole, SH; Furst, DE; Paulus, HE, 1983
)
0.27
" The ideal dosage to obtain a serum salicylate level of 20 mg/100 ml seems to lie between 3 and 4 g of salsalate a day."( Comparison of serum salicylate levels and gastro-intestinal blood loss between salsalate (Disalcid)and other forms of salicylates.
Mielants, H; Verbruggen, G; Veys, EM, 1981
)
0.26
"This study evaluated physicians' use of the occurrence of tinnitus as a tool to establish the optimal dosage of salsalate, a nonacetylated salicylate, in patients with arthritis treated in routine clinical practice."( Assessment of salsalate, a nonacetylated salicylate, in the treatment of patients with arthritis.
Atkinson, MH; Kalish, GH; Ménard, HA,
)
0.13
" Salicylate, unlike aspirin, is only a very weak, reversible inhibitor of cyclooxygenase in clinical doses, and thus is not associated with the potentially dangerous side effects seen with NSAIDs; fully reversible ototoxicity, the dose-limiting side effect in salicylate therapy, can be avoided in most patients by dosage adjustment."( Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome.
McCarty, MF, 2010
)
0.36
" Three PK studies were conducted: (1) PK of SA in normal rats after intravenous dosing of SA at 20, 40, 80 mg/kg."( Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats.
Almon, RR; Cao, Y; DuBois, DC; Jusko, WJ, 2012
)
0.38
"Drug discovery is a complex process with the aim of discovering efficacious molecules where their potency and selectivity are balanced against ADMET properties to set the appropriate dose and dosing interval."( In silico physicochemical parameter predictions.
Barton, P; Wenlock, MC, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
antirheumatic drugA drug used to treat rheumatoid arthritis.
hypoglycemic agentA drug which lowers the blood glucose level.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
EC 3.5.2.6 (beta-lactamase) inhibitorAn EC 3.5.2.* (non-peptide cyclic amide C-N hydrolase) inhibitor that interferes with the action of beta-lactamase (EC 3.5.2.6).
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
benzoate esterEsters of benzoic acid or substituted benzoic acids.
benzoic acidsAny aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
salicylatesAny salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Salsalate Action Pathway2967

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
GLI family zinc finger 3Homo sapiens (human)Potency33.49150.000714.592883.7951AID1259369
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency26.60320.003041.611522,387.1992AID1159552
estrogen nuclear receptor alphaHomo sapiens (human)Potency18.64270.000229.305416,493.5996AID743075; AID743079
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency17.78280.001815.663839.8107AID894
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency10.18150.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (61)

Assay IDTitleYearJournalArticle
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1237123Anti-inflammatory activity in BALB/c mouse assessed as reduction in TPA-induced ear edema by measuring weight of ear punches applied topically in combination with curcumin at at 1:2 mol/mol 6 mins before to TPA treatment2015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Synthesis and biological evaluation of curcumin derivatives containing NSAIDs for their anti-inflammatory activity.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1237112Anti-inflammatory activity in BALB/c mouse model of TPA-induced ear edema assessed as reduction in inflammatory cells infiltration applied topically in combination with curcumin at at 1:2 mol/mol 6 mins before to TPA treatment by H and E staining method2015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Synthesis and biological evaluation of curcumin derivatives containing NSAIDs for their anti-inflammatory activity.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1237124Anti-inflammatory activity in BALB/c mouse model of TPA-induced ear edema assessed as reduction in inflammatory cells infiltration at 0.75 uM applied topically 6 mins before to TPA treatment by H and E staining method2015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Synthesis and biological evaluation of curcumin derivatives containing NSAIDs for their anti-inflammatory activity.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (173)

TimeframeStudies, This Drug (%)All Drugs %
pre-199051 (29.48)18.7374
1990's25 (14.45)18.2507
2000's14 (8.09)29.6817
2010's67 (38.73)24.3611
2020's16 (9.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.68 (24.57)
Research Supply Index5.44 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials42 (22.46%)5.53%
Reviews7 (3.74%)6.00%
Case Studies24 (12.83%)4.05%
Observational0 (0.00%)0.25%
Other114 (60.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (34)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Salsalate Treatment on Insulin Sensitivity and Insulin Secretion in Obese Non-Diabetic Individuals [NCT00339833]Phase 454 participants (Actual)Interventional2003-03-31Completed
Salsalate for the Treatment of Insulin Resistance in People With Schizophrenia [NCT01182727]13 participants (Actual)Interventional2010-08-31Completed
The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study [NCT03222206]Phase 434 participants (Actual)Interventional2017-11-08Completed
Using Salsalate to Target Adipocyte Macrophage Infiltration and Reverse Metabolic Disease Risk in Obese Hispanic Young Adults [NCT02130804]Phase 130 participants (Actual)Interventional2011-07-31Completed
Role of Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclamptic Pregnancy [NCT03482440]Early Phase 132 participants (Anticipated)Interventional2018-08-26Recruiting
Free Fatty Acids-Induced Hypertension, Endothelial Dysfunction, Inflammation, Insulin Resistance, and Autonomic Dysfunction in Lean and Obese Subjects (Aim #2) [NCT02406586]36 participants (Actual)Interventional2009-07-31Completed
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy [NCT02422485]Phase 110 participants (Actual)Interventional2015-04-30Completed
Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction [NCT03229408]Phase 290 participants (Anticipated)Interventional2018-12-05Recruiting
Oral Peri-operative TIming of Metformin (or) Salsalate to Improve Non-cardiac Surgery Glucose Control - A Placebo-Controlled Internal Feasibility Trial [NCT03816488]Phase 10 participants (Actual)Interventional2023-12-01Withdrawn(stopped due to Unable to source salsalate.)
Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy-TINSAL -T1DN [NCT02936843]Phase 2/Phase 361 participants (Actual)Interventional2016-10-31Completed
Effects of Salsalate on Prandial-Induced Vascular Inflammation After SCI [NCT01201759]18 participants (Actual)Interventional2009-07-31Completed
Inflammation Inhibition for Microvascular and Autonomic Dysfunction in Obese Prediabetic Humans [NCT01977417]Phase 221 participants (Actual)Interventional2012-11-30Terminated(stopped due to No funding)
Effect of Physical Inactivity on Endothelial Function [NCT00553995]Phase 160 participants (Actual)Interventional2008-05-31Completed
Targeting Inflammation to Treat Cardiovascular Aging in Humans (TIVA Study) [NCT01775865]Phase 259 participants (Actual)Interventional2012-09-30Completed
Evaluation of the Ovarian Dynamic Response and the Inflammatory Response to Oral Lipid Challenge in Relation to Body Composition in Polycystic Ovary Syndrome [NCT01489319]Phase 147 participants (Actual)Interventional2012-02-29Terminated(stopped due to The PI left Indiana University. The findings served as preliminary data for a recently awarded NIH R01 grant.)
Assessment of the Use of Salsalate to Decrease Endothelial Cell Activation and Inflammation in HIV-infected Adults [NCT01046682]Phase 240 participants (Actual)Interventional2009-01-31Completed
The Study of Inhibition of Inflammation in the Dysmetabolic Syndrome of Obesity [NCT00258115]Phase 220 participants (Actual)Interventional2003-12-31Completed
Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD) [NCT00624923]Phase 2/Phase 3340 participants (Actual)Interventional2008-09-30Completed
Inflammation and Vascular Function in Atherosclerosis [NCT00760019]Phase 2/Phase 358 participants (Actual)Interventional2005-08-31Completed
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate [NCT00799643]Phase 2/Phase 3638 participants (Actual)Interventional2008-11-30Completed
Salsalate as an Adjunctive Treatment for Patients With Schizophrenia [NCT01578486]Phase 417 participants (Actual)Interventional2011-06-30Completed
Effect of Salicylate on Glucose Metabolism in Insulin Resistance States [NCT00258128]Phase 1/Phase 217 participants (Actual)Interventional2000-01-31Completed
Salsalate + Venetoclax/Decitabine for Patients With Acute Myelogenous Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease [NCT04146038]Phase 25 participants (Actual)Interventional2020-10-26Completed
Effects of Fish Oil ± Salsalate on the Omega-3 Index and the Circulating Lipodome of Omega-3 Polyunsaturated Fatty Acid Metabolites in Patients With Type 2 Diabetes and Diabetic Neuropathy [NCT05169060]Phase 1/Phase 2100 participants (Anticipated)Interventional2023-06-12Recruiting
Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk [NCT00330733]Phase 2/Phase 371 participants (Actual)Interventional2007-01-31Completed
Vascular Function, Endothelin, and Inflammation in Pre-diabetic Obesity Versus Lean Healthy Controls [NCT00837590]Phase 116 participants (Actual)Interventional2009-03-31Terminated(stopped due to Preliminary results indicated no measurable benefit.)
A Phase I Study of Salicylate for Adult Patients With Advanced Myelodysplastic Disorders or Acute Myelogenous Leukemia [NCT00004245]Phase 10 participants Interventional1999-08-31Completed
A Pilot Study to Determine the Effects of 12 Weeks of Treatment With Salsalate on Measures of Peripheral Neuropathy in Type 1 Diabetes [NCT01480297]Phase 28 participants (Actual)Interventional2011-11-30Completed
A Randomized, Double-Blind, Placebo Controlled Pilot Trial of Oral Salsalate in the Treatment of the Subset of Unexplained Anemia in Elderly Patients With Elevated Interleukin-6 [NCT01506726]Phase 211 participants (Actual)Interventional2012-03-31Terminated(stopped due to Study drug expiration and supply shortage)
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate [NCT00392678]Phase 2/Phase 3277 participants (Actual)Interventional2006-10-31Completed
Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Endometriosis [NCT05069740]Early Phase 124 participants (Anticipated)Interventional2022-01-01Recruiting
A Phase 1, Single Center, Biomarker Study in Healthy Subjects Receiving Single Doses of CAT-1004 [NCT01670773]Phase 19 participants (Actual)Interventional2012-08-31Completed
Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance? [NCT02007577]41 participants (Actual)Interventional2010-07-31Completed
A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease [NCT03277573]Phase 140 participants (Anticipated)Interventional2017-07-21Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00258128 (2) [back to overview]Glucose
NCT00258128 (2) [back to overview]Adiponectin
NCT00330733 (7) [back to overview]Change in Systemic Glucose Disposal- Glucose Infusion Rates
NCT00330733 (7) [back to overview]Plasma Adiponectin
NCT00330733 (7) [back to overview]Plasma CRP
NCT00330733 (7) [back to overview]Plasma Interleukin 6
NCT00330733 (7) [back to overview]Endothelial Function
NCT00330733 (7) [back to overview]Glucose Area Under the Curve in These Subjects
NCT00330733 (7) [back to overview]Plasma sVCAM
NCT00339833 (2) [back to overview]Change in Fasting Plasma Glucose Concentration
NCT00339833 (2) [back to overview]Change in the Average Serum Insulin Concentration During the Last 40 Min of Clamp
NCT00392678 (7) [back to overview]Change in HbA1c
NCT00392678 (7) [back to overview]Change From Baseline in 14-week Insulin, C-peptide, Homeostasis Model [HOMA] Index
NCT00392678 (7) [back to overview]Change From Baseline and Trends in Fasting Glucose Over Time
NCT00392678 (7) [back to overview]Change in Lipids
NCT00392678 (7) [back to overview]Safety and Tolerability
NCT00392678 (7) [back to overview]Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index
NCT00392678 (7) [back to overview]Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1
NCT00624923 (4) [back to overview]Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months
NCT00624923 (4) [back to overview]Change in Inflammation Marker: CRP
NCT00624923 (4) [back to overview]Change in Cholesterol
NCT00624923 (4) [back to overview]Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT
NCT00760019 (1) [back to overview]Flow-mediated, Endothelium-dependent Vasodilation
NCT00799643 (2) [back to overview]The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.
NCT00799643 (2) [back to overview]Change From Baseline in Fasting Glucose Over Time.
NCT00837590 (1) [back to overview]Vascular Function
NCT01046682 (1) [back to overview]Change in Flow Mediated Dilation (FMD) of the Brachial Artery Measured by Ultrasound Over 13 Weeks
NCT01182727 (1) [back to overview]Side Effects of Salsalate
NCT01201759 (4) [back to overview]Change in Area Under the Curve (AUC) for Glycemia (Glucose) at Visits 2-3 or 4-5 Depending on Order of Treatment Assignment.
NCT01201759 (4) [back to overview]Change in Area Under the Curve (AUC) for Lipemia (Free Fatty Acids ) at Visits 2-3 or 4-5 Depending on Order of Treatment Assignment.
NCT01201759 (4) [back to overview]Change in Area Under the Curve (AUC) for Lipemia (Triglycerides) at Visits 2-3 or 4-5 Depending on Order of Treatment Assignment.
NCT01201759 (4) [back to overview]Change in Fasting Values for Vascular Inflammation IL-6 at Visits 2-3 or 4-5
NCT01480297 (1) [back to overview]Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm
NCT01506726 (18) [back to overview]Change in Frailty Component as Determined by the 4 Meter Walk Speed
NCT01506726 (18) [back to overview]Change in Frailty Component Related to Fatigue/ Exhaustion
NCT01506726 (18) [back to overview]Change in Hemoglobin Level From Baseline to 6 Month Visit
NCT01506726 (18) [back to overview]Change in Markers of Inflammation
NCT01506726 (18) [back to overview]Change in Self Reported Outcomes Measures as Reported by FACIT-AN Total Score
NCT01506726 (18) [back to overview]Change in Self Reported Outcomes Measures as Reported by Short Form-36 (SF-36) Physical Component Score (PCS)
NCT01506726 (18) [back to overview]Change in Serum Hepcidin Levels
NCT01506726 (18) [back to overview]Change in the 6 Minute Walk Test (6MWT) Distance.
NCT01506726 (18) [back to overview]Change in the Frailty Component as Determined by Self-reported Activity Level
NCT01506726 (18) [back to overview]Change in Markers of Inflammation
NCT01506726 (18) [back to overview]Association Between Change in Hemoglobin and Change in Markers of Inflammation.
NCT01506726 (18) [back to overview]Assessment of Serum Biomarkers of Erthropoiesis
NCT01506726 (18) [back to overview]Assessment of Serum Biomarkers of Erthropoiesis
NCT01506726 (18) [back to overview]Change in Cognitive Outcome Measures as Determined by Composite Complex Attention/Executive Processing
NCT01506726 (18) [back to overview]Change in Cognitive Outcome Measures as Determined by Composite Learning and Memory
NCT01506726 (18) [back to overview]Change in Cognitive Outcome Measures as Determined by Speed of Processing
NCT01506726 (18) [back to overview]Change in Cognitive Outcome Measures-Trail Making Test Part B
NCT01506726 (18) [back to overview]Change in Frailty Component as Determined by Grip Strength
NCT01578486 (8) [back to overview]PANSS- Negative Score
NCT01578486 (8) [back to overview]PANSS Positive Score
NCT01578486 (8) [back to overview]MATRICS Composite Score
NCT01578486 (8) [back to overview]IL-6
NCT01578486 (8) [back to overview]Hs-CRP
NCT01578486 (8) [back to overview]TNF-alpha
NCT01578486 (8) [back to overview]SANS Total Score
NCT01578486 (8) [back to overview]PANSS Total Score
NCT01775865 (2) [back to overview]Brachial Artery Flow-mediated Dilation (FMD)
NCT01775865 (2) [back to overview]Carotid-femoral Pulse Wave Velocity (CFPWV)
NCT01977417 (1) [back to overview]Aim 1: Vascular Endothelial Function in Obese Prediabetic Adults Before and After 1 Month of Salsalate or Placebo.
NCT02007577 (2) [back to overview]Quantification of Insulin Clearance With the Graded Glucose Infusion Test (GGIT)
NCT02007577 (2) [back to overview]Quantification of Insulin Action With the Insulin Suppression Test (IST)
NCT02406586 (20) [back to overview]Change in Expression of Inflammatory Biomarker C-Reactive Protein (CRP)
NCT02406586 (20) [back to overview]Change in Expression of Inflammatory Biomarker Interleukin-6 (IL-6)
NCT02406586 (20) [back to overview]Change in FFA (Free Fatty Acid) Levels From Baseline to 6 Weeks
NCT02406586 (20) [back to overview]Change in Flow-mediated Dilation
NCT02406586 (20) [back to overview]Change in Flow-mediated Dilation
NCT02406586 (20) [back to overview]Change in Flow-mediated Dilation
NCT02406586 (20) [back to overview]Change in Systolic Blood Pressure
NCT02406586 (20) [back to overview]Change in Systolic Blood Pressure.
NCT02406586 (20) [back to overview]Change in Systolic Blood Pressure
NCT02406586 (20) [back to overview]Change in Systolic Blood Pressure
NCT02406586 (20) [back to overview]Change in Flow-mediated Dilation
NCT02406586 (20) [back to overview]Change in Systolic Blood Pressure
NCT02406586 (20) [back to overview]Change in Systolic Blood Pressure
NCT02406586 (20) [back to overview]Change in Systolic Blood Pressure
NCT02406586 (20) [back to overview]Change in Systolic Blood Pressure
NCT02406586 (20) [back to overview]Change in Systolic Blood Pressure
NCT02406586 (20) [back to overview]Change in Systolic Blood Pressure
NCT02406586 (20) [back to overview]Change in Systolic Blood Pressure
NCT02406586 (20) [back to overview]Change in Systolic Blood Pressure
NCT02406586 (20) [back to overview]Change in Diastolic Blood Pressure From Baseline to 6 Weeks
NCT04146038 (2) [back to overview]Number of Participants Experiencing Adverse Events Incidence With of Salicylate + Venetoclax + Decitabine
NCT04146038 (2) [back to overview]Number of Participants With Complete or Partial Response

Glucose

fasting glucose (NCT00258128)
Timeframe: 4 weeks

Interventionmmol/L (Mean)
Placebo7.1
Salsalate6.4

[back to top]

Adiponectin

(NCT00258128)
Timeframe: 4 weeks

Interventionmg/ml (Mean)
Salsalate22.7
Placebo10.6

[back to top]

Change in Systemic Glucose Disposal- Glucose Infusion Rates

Participants were admitted to the Clinical Research Units at 06:00-08:00 hours after an overnight fast. Euglycaemic-hyperinsulinaemic clamps were conducted at baseline and at the end of the study. Because salsalate therapy appears to decrease insulin clearance leading to higher circulating insulin levels during the clamp, we reduced the infusion rate of insulin in the active treatment arm by 20% (from 100 to 80 mUm-2 min-1) at the study end. Insulin solutions were prepared by the site pharmacist so that study staff remained blinded to drug assignment. Whole-body insulin sensitivity was estimated from glucose infusion rate (GIR) during last 30 min of insulin infusions. (NCT00330733)
Timeframe: 3 months

Interventionpercent change from baseline (Median)
Placebo1
Salsalate Therapy6

[back to top]

Plasma Adiponectin

Plasma soluble Adiponectin was measured by ELISA. Data are reported as change from baseline at 8 and 12 weeks. (NCT00330733)
Timeframe: 8 and 12 weeks

,
Interventionμg/ml (Median)
Change in adiponectin at 8 weeksChange in adiponectin at 12 weeks
Placebo-0.5-0.1
Salsalate Therapy1.31.2

[back to top]

Plasma CRP

Plasma C-reactive protein was measured by PVAHS clinical laboratory. Data are reported as change from baseline at 8 and 12 weeks. (NCT00330733)
Timeframe: 8 and 12 weeks

,
Interventionmg/l (Median)
Change in CRP at 8 weeksChange in CRP at 12 weeks
Placebo0-0.1
Salsalate Therapy-0.8-.3

[back to top]

Plasma Interleukin 6

Plasma IL-6 was measured by ELISA. Data are reported as change from baseline at 8 and 12 weeks. (NCT00330733)
Timeframe: 8 and 12 weeks

,
Interventionpg/ml (Median)
Change in IL-6 at 8 weeksChange in IL-6 at 12 weeks
Placebo0.10.2
Salsalate Therapy00

[back to top]

Endothelial Function

Endothelial-mediated arterial responses using peripheral arterial tonometry (PAT; Itamar Medical, Caesarea, Israel). (NCT00330733)
Timeframe: Baseline and 12 weeks

,
Interventionindex (Mean)
Pat Index baselinePat Index 12 week
Placebo1.81.7
Salsalate Therapy1.91.7

[back to top]

Glucose Area Under the Curve in These Subjects

(NCT00330733)
Timeframe: 3 months

Interventionmmol/l/hr (Mean)
Placebo8.98
Salsalate Therapy8.74

[back to top]

Plasma sVCAM

Plasma soluble VCAM was measured by ELISA. Data are reported as change from baseline at 8 and 12 weeks. (NCT00330733)
Timeframe: 8 and 12 weeks

,
Interventionng/ml (Median)
Change in sVCAM at 8 weeksChange in sVCAM at 12 weeks
Placebo-129
Salsalate Therapy-5171

[back to top]

Change in Fasting Plasma Glucose Concentration

(NCT00339833)
Timeframe: 7 days

Interventionmmol/l (Mean)
Salsalate4.7
Placebo0.0

[back to top]

Change in the Average Serum Insulin Concentration During the Last 40 Min of Clamp

(NCT00339833)
Timeframe: last 40 min of clamp

Interventionl/min (Mean)
Salsalate0.15
Placebo-0.06

[back to top]

Change in HbA1c

Change from baseline to either 14 or 26 weeks, or last HbA1c measurement prior to rescue therapy (NCT00392678)
Timeframe: 14 week

Intervention% HbA1c (Mean)
Placebo0
Salsalate 3.0 g/d-0.4
Salsalate 3.5 g/d-0.3
Salsalate 4.0 g/d-0.5

[back to top]

Change From Baseline in 14-week Insulin, C-peptide, Homeostasis Model [HOMA] Index

HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in insulin from Baseline to Week 14 in data table below. (NCT00392678)
Timeframe: Baseline, week 14

Interventionpmol/l (Median)
Placebo-3.0
Salsalate 3.0 g/d15
Salsalate 3.5 g/d7.6
Salsalate 4.0 g/d27

[back to top] [back to top]

Change in Lipids

"Change in lipids (low-density lipoprotein cholesterol [LDL-C], non-high-density lipoprotein cholesterol [non-HDL-C], triglycerides [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL C], TC/HDL-C ratio, and LDL-C/HDL-C ratio)~LDL-C/HDL-C ratio not calculated" (NCT00392678)
Timeframe: 14 week

,,,
Interventionmg/dl (Mean)
CholesterolHDLLDLTGTotal to HDL ratio
Placebo000150
Salsalate 3.0 g/d8315-340.1
Salsalate 3.5 g/d-113-22-0.1
Salsalate 4.0 g/d628-160.2

[back to top]

Safety and Tolerability

See adverse event module for details. Safety and tolerability of salsalate compared to placebo as assessed by adverse events. (NCT00392678)
Timeframe: 14 weeks

Interventionparticipants (Number)
Salsalate 3.0 g/d17
Salsalate 3.5 g/d16
Salsalate 4.0 g/d16
Placebo14

[back to top]

Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index

HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in C-peptide from Baseline to Week 14 is in the data table below (NCT00392678)
Timeframe: Baseline, week 14

InterventionC-peptide in nmol/l (Mean)
Placebo0.10
Salsalate 3.0 g/d-0.07
Salsalate 3.5 g/d-0.03
Salsalate 4.0 g/d0.03

[back to top]

Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1

The primary outcome for the TINSAL-T2D study is change in HbA1c level from baseline to week 14 (stage 1) in the intent-to-treat (ITT) population with last observation carried forward. (NCT00392678)
Timeframe: 14 week

Intervention% (units of HbA1c) (Mean)
3.0 g/d-0.36
3.5 g/d-0.34
4.0 g/d-0.49
Placebo-0.01

[back to top]

Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months

(NCT00624923)
Timeframe: Baseline to 30 months

Interventionmm^3 (Mean)
1- Active Pharmacologic0
2-Placebo0

[back to top]

Change in Inflammation Marker: CRP

Secondary outcome of change in inflammation marker CRP (NCT00624923)
Timeframe: baseline to 30 mo

Interventionmg/L (Mean)
1- Active Pharmacologic-0.1
2- Placebo-0.1

[back to top]

Change in Cholesterol

secondary (NCT00624923)
Timeframe: Baseline to 30 mo

Interventionmg/dL (Mean)
1- Active Pharmacologic5.1
2- Placebo2.0

[back to top]

Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT

Secondary outcome, change in liver inflammation associated with NASH: ALT (NCT00624923)
Timeframe: baseline to 30 mo

InterventionU/L (Mean)
1- Active Pharmacologic-1.1
2- Placebo-0.6

[back to top]

Flow-mediated, Endothelium-dependent Vasodilation

Flow-mediated, endothelium-dependent vasodilation (percentage increase in brachial artery diameter after a 5 minute ischemic stimulus) measured at the end of placebo treatment and end of salsalate treatment were compared. (NCT00760019)
Timeframe: Upon completion of 4 weeks of salsalate and placebo treatment

Interventionpercentage vasodilation (Median)
Salsalate6.8
Placebo8.7

[back to top]

The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.

HbA1c (%, percentage of HbA1c) change from baseline. (NCT00799643)
Timeframe: 48 weeks from baseline

InterventionHbA1c units are % (Mean)
Placebo-0.04
Salsalate-0.33

[back to top]

Change From Baseline in Fasting Glucose Over Time.

(NCT00799643)
Timeframe: 48 weeks from baseline

Interventionmg/dl (Mean)
Placebo2.0
Salsalate-13.1

[back to top]

Vascular Function

The primary endpoints of interest is flow-mediated vasodilation (NCT00837590)
Timeframe: Measured at baseline and after a single oral dose of salsalate (Acute) or 2 months' treatment with salsalate (Chronic)

,,
Interventionml/min (Mean)
BaselineSalsalate
Acute Salsalate5.45.6
Chronic Salsalate - Lean8.37.5
Chronic Salsalate - Obese6.74.4

[back to top]

Change in Flow Mediated Dilation (FMD) of the Brachial Artery Measured by Ultrasound Over 13 Weeks

Flow mediated dilation (FMD) of the brachial artery was measured by ultrasound. This is a measure of endothelial dependent endothelial cell function. Flow mediated dilation is expressed as a percent change from baseline brachial artery diameter to brachial artery diameter after reactive hyperemia. Reactive hyperemia occurred after occluding the brachial artery with a blood pressure cuff for 5 minutes. (NCT01046682)
Timeframe: Entry and week 13 visits

Intervention% change from baseline (Median)
Salsalate0.99
Usual Care-0.07

[back to top]

Side Effects of Salsalate

This Measure is reporting the number of participants with side effects as reported on the Side Effect Checklist used to monitor common medication side effects. (NCT01182727)
Timeframe: 6 weeks

Interventionparticipants (Number)
Salsalate3

[back to top]

Change in Area Under the Curve (AUC) for Glycemia (Glucose) at Visits 2-3 or 4-5 Depending on Order of Treatment Assignment.

"The postprandial glycemia is assessed by the change in the AUC for plasma glucose sampled before and after intervention at time points of 0 (immediately post-feeding) to 480 min.~For peak Glucose, and Glucose area under the curve (AUC), treatments (placebo and salsalate) and visits (pre and post treatment) were defined as within-subject's factors." (NCT01201759)
Timeframe: Blood samples for each visit were sampled at 0 (immediately post-feeding), and 30,60,90,120,240,360,480 min post-feeding..

Interventionmg*min/dL (Mean)
Placebo1
Salsalate-8

[back to top]

Change in Area Under the Curve (AUC) for Lipemia (Free Fatty Acids ) at Visits 2-3 or 4-5 Depending on Order of Treatment Assignment.

"The postprandial lipemia is assessed by the change in the AUC for plasma Free fatty acids (FFA)sampled before and after intervention at time points of 0min immediately post feeding to 480 min.~For peak FFA area under the curve (AUC), treatments (placebo and salsalate) and visits (pre and post treatment) were defined as within-subject's factors." (NCT01201759)
Timeframe: Each visit sampled at 0 (immediately post-feeding), and 30,60,90,120,240,360,480 min post-feeding..

Interventionmg*min/dL (Mean)
Placebo8
Salsalate-111

[back to top]

Change in Area Under the Curve (AUC) for Lipemia (Triglycerides) at Visits 2-3 or 4-5 Depending on Order of Treatment Assignment.

"The postprandial lipemia is assessed by the change in the AUC for plasma triglycerides sampled before and after intervention at time points 0 (immediately post-feeding)to 480 min.~For peak TG, and TG area under the curve (AUC), treatments (placebo and salsalate) and visits (pre and post treatment) were defined as within-subject's factors." (NCT01201759)
Timeframe: Each visit samples at 0 (immediately post-feeding), and 30,60,90,120,240,360,480 min post-feeding..

Interventionmg*min/dL (Mean)
Placebo-34
Salsalate-62

[back to top]

Change in Fasting Values for Vascular Inflammation IL-6 at Visits 2-3 or 4-5

"The pro-atherogenic inflammatory mediators are assessed by the change in fasting values of Interleukin-6 in plasma concentration Pre and Post intervention at -30 min ( fasting).~For fasting values treatments (placebo and salsalate) and visits (pre and post) were defined as within subject's factors." (NCT01201759)
Timeframe: Study visit at min -30 (fasting)

,
Interventionmg/dL (Mean)
Pre-InterventionPost-Intervention
Placebo0.480.50
Salsalate0.510.19

[back to top]

Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm

Intra-epidermal Nerve Fiber Density (IENFD) was measured at two anatomic locations (thigh and ankle) at baseline and after 12 weeks of treatment with Salsalate. IENFD is expressed as fibers per mm. Means and standard deviations are shown. (NCT01480297)
Timeframe: Baseline and 12 weeks

Interventionfibers per mm (Mean)
Baseline Thigh IENFD(fibers per mm)Baseline Ankle IENFD(fibers per mm)12 Week Thigh IENFD(fibers per mm)12 Week Ankle IENFD(fibers per mm)
Salsalate6.33.05.23.0

[back to top]

Change in Frailty Component as Determined by the 4 Meter Walk Speed

"To quantify the impact of anemia treatment by salsalate on change in the speed of the 4 meter walk speed. Subjects are asked to walk as fast as they can for 4 meters. Frailty was determined by the subject's speed. (change from frail at baseline to not frail at 6 months). 4 m walking speed is stratified by gender and height. For men, (height of <= 173 cm and a walking speed of <= 0.65 meter/sec) or a (height > 173, <= .76 meter/sec) were classified as frail. For women, (height of <= 159 cm and a walking speed of <=.65 meter/sec) or (height >159 cm <= 0.76 meter/sec) were classified as frail.The outcome is the number of participants who were classified as frail at baseline and changed to not frail at 6 months." (NCT01506726)
Timeframe: baseline; 6 months

Interventionparticipants (Number)
Active Drug - Oral Salsalate0
Placebo Arm0

[back to top] [back to top]

Change in Hemoglobin Level From Baseline to 6 Month Visit

To test whether the administration of oral salsalate to a subset of elderly subjects with unexplained anemia (UAE) and high interleukin (IL-6) levels will improve hemoglobin level (NCT01506726)
Timeframe: baseline; 6 months

Interventiong/dL (Mean)
Active Drug - Oral Salsalate0.06
Placebo Arm1.00

[back to top]

Change in Markers of Inflammation

To assess whether oral salsalate reduces C-reactive protein (CRP) in UAE subjects. Change in the CRP from prior to study drug to 6 months. (NCT01506726)
Timeframe: prior to study drug; 6 months

Interventionug/ml (Mean)
Active Drug - Oral Salsalate-1.976
Placebo Arm1.890

[back to top]

Change in Self Reported Outcomes Measures as Reported by FACIT-AN Total Score

To quantify the impact of anemia treatment by salsalate on self -reported outcomes measures by subjects answering 47 questions for patients with anemia and or fatigue. This test detects self-report functional changes and QoL. Change from baseline to 6 months. Scores range from 0-188 with higher scores indicating better function. (NCT01506726)
Timeframe: baseline; 6 months

Interventionscores on a scale (Mean)
Active Drug - Oral Salsalate18.9
Placebo Arm7.7

[back to top]

Change in Self Reported Outcomes Measures as Reported by Short Form-36 (SF-36) Physical Component Score (PCS)

To quantify the impact of anemia treatment by salsalate on self-reported outcomes measures by change in SF36 physical component score. The SF-36 form identifies self-report physical function and global measure of quality of life and is a multi-purpose, short-form health survey consisting of 36 questions. The Physical Component Summary (PCS) is a subscale of the SF-36 that correlates with physical health domains of the SF-36 ( Physical Function, Role-Physical, and Bodily Pain). The change is calculated and compared from baseline to 6 months. The SF-36 PCS score is a norm based sore with a mean of 50 and standard deviation of 10 where results above and below 50 are above and below the average, respectively, in the 2009 general US population. (NCT01506726)
Timeframe: baseline; 6 months

Interventiont score (Mean)
Active Drug - Oral Salsalate1.63
Placebo Arm3.77

[back to top]

Change in Serum Hepcidin Levels

To compare the change in serum hepcidin levels between treatment groups and whether such a change is proportional to the decline in IL-6 levels. Change in the hepcidin from prior to study drug to 6 months. Positive changes represent increases in hepcidin levels and negative changes represent decreases. (NCT01506726)
Timeframe: prior to study drug; 6 months

Interventionng/ml (Mean)
Active Drug - Oral Salsalate0.879
Placebo Arm15.462

[back to top]

Change in the 6 Minute Walk Test (6MWT) Distance.

To assess the impact of treatment of anemia with oral salsalate will improve 6 minute walk test (6MWT) distance from baseline to 6 months as measured in meters and centimeters. (NCT01506726)
Timeframe: baseline; 6 months

Interventionmeters (Mean)
Active Drug - Oral Salsalate-20.77
Placebo Arm29.24

[back to top]

Change in the Frailty Component as Determined by Self-reported Activity Level

"To quantify the impact of anemia treatment by salsalate on change in the frailty as measured by change in self-reported activity level. Frailty for activity level is classified by subjects responses to 6physical activity questions on the short version of the Minnesota Leisure Time Activity Questionnaire , were related to walking for exercise, moderately strenuous outdoor chores, dancing, bowling, and regular exercise. The Women's Health And Aging Study (WHAS) scoring algorithm was used to define frailty for self-reported activity level. The answers to these questions were used to calculate kilocalories (Kcals) per week, using the WHAS algorithm, which is further satisfied by by gender. For men, Kcals < 128 per week is frail. For women, Kcals < 90 per week is frail. This is a categorical measurement of yes or no. The outcome is the number of participants who were classified as frail at baseline and changed to not frail at 6 months." (NCT01506726)
Timeframe: baseline; 6 months

Interventionparticipants (Number)
Active Drug - Oral Salsalate1
Placebo Arm0

[back to top]

Change in Markers of Inflammation

To assess whether oral salsalate reduces markers of inflammation including IL-6 and Tumor Necrosis Factor Receptor1 (TNF-R1) in UAE subjects. Change in the marker from prior to study drug to 6 months. (NCT01506726)
Timeframe: prior to study drug; 6 months

,
Interventionpg/ml (Mean)
IL6Tumor Necrosis Factor Receptor1 (TNF-R1),
Active Drug - Oral Salsalate-1.096133.48
Placebo Arm0.703-189.40

[back to top]

Association Between Change in Hemoglobin and Change in Markers of Inflammation.

To examine whether there is an association between change in hemoglobin and changes in markers of inflammation from prior to study drug to 6 months. Inflammatory markers to be measured are iL-6, Tumor Necrosis Factor alpha Receptor1 (TNF-R1), and C-reactive protein (CRP) in anemia subjects.Correlation between change in the inflammatory markers and the change in HB from prior to study drug to 6 months. (NCT01506726)
Timeframe: prior to study drug; 6 months

,
Interventioncorrelation coefficient (Number)
IL6 correlationTNF correlationCRP correlation
Active Drug - Oral Salsalate-0.1130.9480.156
Placebo Arm-0.446-0.977-0.166

[back to top]

Assessment of Serum Biomarkers of Erthropoiesis

To assess whether oral salsalate improves serum biomarkers of erythropoiesis by decreasing growth differentiation factor-15 (GDF-15) in UAE subjects. Change in the GDF-15 from prior to study drug to 6 months. (NCT01506726)
Timeframe: prior to study drug; 6 months

Interventionpg/ml (Mean)
Active Drug - Oral Salsalate16.688
Placebo Arm187.240

[back to top]

Assessment of Serum Biomarkers of Erthropoiesis

To assess whether oral salsalate improves serum biomarkers of erythropoiesis by increasing erythropoietin (Epo) in UAE subjects. Change in the Epo from prior to study drug to 6 months. (NCT01506726)
Timeframe: prior to study drug; 6 months

InterventionmIU/ml (Mean)
Active Drug - Oral Salsalate-0.014
Placebo Arm-1.540

[back to top]

Change in Cognitive Outcome Measures as Determined by Composite Complex Attention/Executive Processing

To quantify the impact of anemia treatment by salsalate on cognitive outcomes based on Complex attention/executive processing was derived using the z-scores of the following three tests: (1) TMT Part B seconds per completed circle, (2) time score from the CogState One Back Task, and (3) accuracy score from the CogState One Back Task. The composite score for a subject at each time point was defined as the mean of the Z-scores for the three tests at the time point. For each subject, the Z-score for each test at time point was derived by subtracting the overall baseline mean of the test from the subject's score at the time point (accuracy score) or by subtracting the subject's score at the time point from the overall baseline mean of the test (TMT and time score) and then dividing by the overall baseline standard deviation of the test. Positive z-scores indicate a better performance compared to the baseline average. The change in the Z-score from baseline to month 6. (NCT01506726)
Timeframe: baseline; 6 months

Interventionchange in Z-Score (Mean)
Active Drug - Oral Salsalate0.71
Placebo Arm-0.07

[back to top]

Change in Cognitive Outcome Measures as Determined by Composite Learning and Memory

To quantify the impact of anemia treatment by salsalate on cognitive outcomes based on Learning and memory was derived using the z-scores of the following three tests: (1) CogState ISL immediate recall score (total score from three learning trials), (2) CogState ISL immediate recall score from the first learning trial, and (3) CogState ISL delayed recall scores. The composite score for a subject at each time point was defined as the mean of the Z-scores for the three tests at the time point. For each subject, the Z-score for each test at time point was derived by subtracting the overall baseline mean of the test from the subject's score at the time point and then dividing by the overall baseline standard deviation of the test. Positive z-scores indicate a better performance compared to the baseline average. The change in the Z-score from baseline to month 6. (NCT01506726)
Timeframe: baseline; 6 months

Interventionchange in Z-Score (Mean)
Active Drug - Oral Salsalate0.15
Placebo Arm-0.34

[back to top]

Change in Cognitive Outcome Measures as Determined by Speed of Processing

To quantify the impact of anemia treatment by salsalate on cognitive outcomes based on speed of processing was derived using the z-scores of the following three tests: (1) TMT Part A seconds per completed circle, (2) simple reaction time from the CogState Detection Task, and (3) choice reaction time from the CogState Identification Task. The composite score for a subject at each time point was defined as the mean of the Z-scores for the three tests at the time point. For each subject, the Z-score for each test at time point was derived by subtracting the subject's score at the time point from the overall baseline mean of the test and then dividing by the overall baseline standard deviation of the test. Positive z-scores indicate a better performance compared to the baseline average.The change in the Z-score from baseline to month 6. (NCT01506726)
Timeframe: baseline; 6 months

Interventionchange in Z-Score (Mean)
Active Drug - Oral Salsalate0.29
Placebo Arm1.42

[back to top]

Change in Cognitive Outcome Measures-Trail Making Test Part B

To quantify the impact of anemia treatment by salsalate on cognitive outcomes based on the Trail Making Test (TMT) Part B as measured by subjects drawing a line from 25 circled numbers to letters in 300 seconds. The change in seconds per completed circle from baseline to month 6. (NCT01506726)
Timeframe: baseline; 6 months

Interventionsecond per completed circle (Mean)
Active Drug - Oral Salsalate-0.18
Placebo Arm1.23

[back to top]

Change in Frailty Component as Determined by Grip Strength

"To quantify the impact of anemia treatment by salsalate on change in the frailty as measured by change in grip strength. Subjects squeeze the grip strength machine 3 times with each hand. For the frailty outcome the maximum grip strength from the dominant hand is used. (change from frail at baseline to not frail at 6 months). Grip strength is stratified by gender and BMI. For men with (BMI <= 24 and a grip strength (GS) <= 29) or (BMI 24.1-28 and grip strength <= 30) or (BMI >28 and a grip strength <= 32) were classified as frail. For women with (BMI <= 23 and a grip strength of <= 17) or (BMI 23.1-26 and a GS <= 17.3) or (BMI 26.1-29 and a GS <= 18) or (BMI > 29 and a GS <= 21) were classified as frail.The outcome is the number of participants who were classified as frail at baseline and changed to not frail at 6 months." (NCT01506726)
Timeframe: baseline; 6 months

Interventionparticipants (Number)
Active Drug - Oral Salsalate0
Placebo Arm1

[back to top]

PANSS- Negative Score

Subscale of Positive and Negative Syndrome Scale that specifically measures negative symptoms. The scores range from 7-49, with higher scores representing a worse outcome. (NCT01578486)
Timeframe: Baseline, 12 weeks

Interventionunits on a scale (Mean)
BaselineWeek 12
Salsalate18.517.4

[back to top]

PANSS Positive Score

Subscale of Positive and Negative Syndrome Scale that specifically measures positive symptoms. The scores range from 7-49, with higher scores representing a worse outcome. (NCT01578486)
Timeframe: Baseline, 12 weeks

Interventionunits on a scale (Mean)
BaselineWeek 12
Salsalate13.010.9

[back to top]

MATRICS Composite Score

Improved cognition will be measured using the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) assessment. The MATRICS assessment includes a battery of tests, and the composite t-score measures cognition across 7 domains including speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. A higher score indicates better cognition. (NCT01578486)
Timeframe: Baseline, 12 weeks

Interventiont-score (Mean)
BaselineWeek 12
Salsalate27.931.6

[back to top]

IL-6

IL-6 (interleukin 6) is a marker used to measure inflammation. (NCT01578486)
Timeframe: Baseline, week 12

Interventionpg/mL (Mean)
BaselineWeek 12
Salsalate2.22.3

[back to top]

Hs-CRP

High-sensitivity C-reactive protein (hs-CRP) will be measured in mg/L in order to detect inflammation. Higher hs-CRP values correspond to higher levels of inflammation. (NCT01578486)
Timeframe: Baseline, 12 weeks

Interventionmg/L (Mean)
BaselineWeek 12
Salsalate3.02.0

[back to top]

TNF-alpha

Tumor necrosis-alpha factor will be measured to assess inflammation levels. (NCT01578486)
Timeframe: Baseline,12 weeks

Interventionpg/ml (Mean)
BaselineWeek 12
Salsalate8.28.7

[back to top]

SANS Total Score

Negative symptoms of schizophrenia will be measured by total score on the Scale for Assessment of Negative Symptoms (SANS; score range 0-100). Higher scores correspond with worse outcomes. (NCT01578486)
Timeframe: Baseline, 12 weeks

Interventionunits on a scale (Mean)
BaselineWeek 12
Salsalate33.033.0

[back to top]

PANSS Total Score

Positive and negative symptoms of schizophrenia will be measured by total score on all subscales of the Positive and Negative Syndrome Scale (PANSS; score range 30-210). Higher scores correspond with worse outcomes. (NCT01578486)
Timeframe: Baseline and 12 weeks

Interventionunits on a scale (Mean)
BaselineWeek 12
Salsalate58.253.5

[back to top]

Brachial Artery Flow-mediated Dilation (FMD)

Endothelial function (NCT01775865)
Timeframe: Change from baseline brachial artery FMD at 4 weeks

,,
InterventionPercent dilation (Mean)
Baseline4 Weeks
Placebo3.572.50
Salsalate3.494.60
Young Control Group5.88NA

[back to top]

Carotid-femoral Pulse Wave Velocity (CFPWV)

Aortic stiffness (NCT01775865)
Timeframe: Change in CFPWV from baseline at 4 weeks

,,
Interventioncm/sec (Mean)
Baseline4 weeks
Placebo785.1740.01
Salsalate831.3839.6
Young Control Group538.0NA

[back to top]

Aim 1: Vascular Endothelial Function in Obese Prediabetic Adults Before and After 1 Month of Salsalate or Placebo.

Brachial artery flow-mediated dilation (NCT01977417)
Timeframe: Change from baseline at 4 weeks

Intervention% dilation (Mean)
Salsalate5.57
Placebo6.98

[back to top]

Quantification of Insulin Clearance With the Graded Glucose Infusion Test (GGIT)

compare changes in insulin clearance as assessed by the GGIT before and after treatment with salsalate to placebo (NCT02007577)
Timeframe: one month on treatment

Interventionpmol/min x 4h (Median)
Salsalate 3500mg in 2 Divided Doses a Day-6
Placebo0

[back to top]

Quantification of Insulin Action With the Insulin Suppression Test (IST)

Compare changes in insulin sensitivity as assesses by the IST before and after treatment between salsalate and placebo group (NCT02007577)
Timeframe: after treatment for one month

Interventionmmol/L (Median)
Salsalate 3500mg in 2 Divided Doses a Day-3
Placebo2

[back to top]

Change in Expression of Inflammatory Biomarker C-Reactive Protein (CRP)

It is measured by using microsphere-based flow cytometric immunoassay. Change is the difference between 6-week inflammatory biomarker level from baseline level. (NCT02406586)
Timeframe: Baseline, 6 weeks

Interventionmg/dL (Mean)
Salsalate2.55
Carvedilol-7.08
Placebo-0.20

[back to top]

Change in Expression of Inflammatory Biomarker Interleukin-6 (IL-6)

It is measured by using microsphere-based flow cytometric immunoassay. Change is the difference between 6-week level from baseline level. (NCT02406586)
Timeframe: Baseline, 6 weeks

Interventionpg/ml (Mean)
Salsalate-0.29
Carvedilol-1.84
Placebo-0.36

[back to top]

Change in FFA (Free Fatty Acid) Levels From Baseline to 6 Weeks

Blood samples were collected for measurement of free fatty acids at baseline and 6 weeks after the Intralipid 20% infusion. FFA levels were determined by colorimetric method. Current guidelines identify normal range of FFA level as less than 0.72 mmol/L. Elevated plasma levels of FFA indicate a greater rate of insulin resistance. Change is the difference between 6-week FFA levels from baseline FFA levels. (NCT02406586)
Timeframe: Baseline, 6 weeks

Interventionmmol/L (Mean)
Salsalate-0.08
Carvedilol0.04
Placebo0.03

[back to top]

Change in Flow-mediated Dilation

The change in endothelium-dependent vascular reactivity will be measured by flow-mediated dilation (FMD) of the brachial artery using a high-resolution vascular ultrasound with a 10-MHz linear array transducer. FMD is expressed as the percentage increase in diameter at the baseline visit from pre-dosing with Intralipid to 12 hours during Intralipid infusion. (NCT02406586)
Timeframe: Pre-dose (Baseline), within 12 hours at Baseline visit

Interventionpercent change in diameter (Mean)
Salsalate0.14
Carvedilol0.24
Placebo0.26

[back to top]

Change in Flow-mediated Dilation

The change in endothelium-dependent vascular reactivity will be measured by flow-mediated dilation (FMD) of the brachial artery using a high-resolution vascular ultrasound with a 10-MHz linear array transducer. FMD is expressed as the percentage increase in diameter at the baseline visit from pre-dosing with Intralipid to 24 hours during Intralipid infusion (NCT02406586)
Timeframe: Pre-dose (Baseline), within 24 hours at Baseline visit

Interventionpercent change in diameter (Mean)
Salsalate0.35
Carvedilol0.53
Placebo0.47

[back to top]

Change in Flow-mediated Dilation

The change in endothelium-dependent vascular reactivity will be measured by flow-mediated dilation (FMD) of the brachial artery using a high-resolution vascular ultrasound with a 10-MHz linear array transducer. FMD is expressed as the percentage increase in diameter at the Week 6 visit from pre-dosing with Intralipid to 12 hours during Intralipid infusion. (NCT02406586)
Timeframe: Pre-dose (Week 6), within 12 hours at Week 6 visit

Interventionpercent change in diameter (Mean)
Salsalate0.22
Carvedilol0.42
Placebo0.20

[back to top]

Change in Systolic Blood Pressure

Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at the baseline visit from pre-dosing with Intralipid to 20 hours during Intralipid infusion. (NCT02406586)
Timeframe: Pre-dose (Baseline), within 20 hours at Baseline visit

InterventionmmHg (Mean)
Salsalate13.27
Carvedilol9.39
Placebo11.4

[back to top]

Change in Systolic Blood Pressure.

Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at the baseline visit from pre-dosing with Intralipid to 4 hours during Intralipid infusion. (NCT02406586)
Timeframe: Pre-dose (Baseline), within 4 hours at Baseline visit

InterventionmmHg (Mean)
Salsalate15.37
Carvedilol10.04
Placebo10.25

[back to top]

Change in Systolic Blood Pressure

Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. from Change is the difference in systolic blood pressure at the baseline visit from pre-dosing with Intralipid to 8 hours during Intralipid. (NCT02406586)
Timeframe: Pre-dose (Baseline), within 8 hours at Baseline visit

InterventionmmHg (Mean)
Salsalate13.02
Carvedilol2.03
Placebo5.47

[back to top]

Change in Systolic Blood Pressure

Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at the baseline visit from pre-dosing with Intralipid to 16 hours during Intralipid infusion. (NCT02406586)
Timeframe: Pre-dose (Baseline), within 16 hours at Baseline visit

InterventionmmHg (Mean)
Salsalate15.78
Carvedilol8.05
Placebo3.6

[back to top]

Change in Flow-mediated Dilation

The change in endothelium-dependent vascular reactivity will be measured by flow-mediated dilation (FMD) of the brachial artery using a high-resolution vascular ultrasound with a 10-MHz linear array transducer. FMD is expressed as the percentage increase in diameter at the Week 6 visit from pre-dosing with Intralipid to 24 hours during Intralipid infusion (NCT02406586)
Timeframe: Pre-dose (Week 6), within 24 hours at Week 6 visit

Interventionpercent change in diameter (Mean)
Salsalate0.39
Carvedilol0.70
Placebo0.48

[back to top]

Change in Systolic Blood Pressure

Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at the baseline visit from pre-dosing with Intralipid to 12 hours during Intralipid infusion. (NCT02406586)
Timeframe: Pre-dose (Baseline), within 12 hours at Baseline visit

InterventionmmHg (Mean)
Salsalate20.55
Carvedilol1.74
Placebo5.25

[back to top]

Change in Systolic Blood Pressure

Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure from at Week 6 from pre-dosing with Intralipid to 8 hours during Intralipid infusion. (NCT02406586)
Timeframe: Pre-dose (Week 6), within 8 hours at Week 6 visit

InterventionmmHg (Mean)
Salsalate10.1
Carvedilol11.62
Placebo4.14

[back to top]

Change in Systolic Blood Pressure

Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at Week 6 from pre-dosing with Intralipid to 4 hours during Intralipid infusion. (NCT02406586)
Timeframe: Pre-dose (Week 6), within 4 hours at Week 6 visit

InterventionmmHg (Mean)
Salsalate11.50
Carvedilol14.32
Placebo4.26

[back to top]

Change in Systolic Blood Pressure

Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at Week 6 from pre-dosing with Intralipid to 24 hours during Intralipid infusion. (NCT02406586)
Timeframe: Pre-dose (Week 6), within 24 hours at Week 6 visit

InterventionmmHg (Mean)
Salsalate11.23
Carvedilol9.92
Placebo3.04

[back to top]

Change in Systolic Blood Pressure

Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at Week 6 from pre-dosing with Intralipid to 20 hours during Intralipid infusion. (NCT02406586)
Timeframe: Pre-dose (Week 6), within 20 hours at Week 6 visit

InterventionmmHg (Mean)
Salsalate12.88
Carvedilol8.84
Placebo6.6

[back to top]

Change in Systolic Blood Pressure

Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at Week 6 from pre-dosing with Intralipid to 16 hours during Intralipid infusion. (NCT02406586)
Timeframe: Pre-dose (Week 6), within 16 hours at Week 6 visit

InterventionmmHg (Mean)
Salsalate7.85
Carvedilol7.55
Placebo-0.04

[back to top]

Change in Systolic Blood Pressure

Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at Week 6 from pre-dosing with Intralipid to 12 hours during Intralipid infusion. (NCT02406586)
Timeframe: Pre-dose (Week 6), within 12 hours at Week 6 visit

InterventionmmHg (Mean)
Salsalate9.50
Carvedilol8.14
Placebo0.38

[back to top]

Change in Systolic Blood Pressure

Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at the baseline visit from pre-dosing with Intralipid to 24 hours during Intralipid infusion. (NCT02406586)
Timeframe: Pre-dose (Baseline), within 24 hours at Baseline visit

InterventionmmHg (Mean)
Salsalate13.93
Carvedilol13.21
Placebo10.27

[back to top]

Change in Diastolic Blood Pressure From Baseline to 6 Weeks

Diastolic blood pressure is the amount of pressure in the arteries when the heart is at rest between beats. Current guidelines identify normal diastolic blood pressure as lower than 80 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 8 hour infusion with subjects in supine position. Change is the difference between 6-week diastolic blood pressure from baseline diastolic blood pressure. (NCT02406586)
Timeframe: Baseline, 6 weeks

InterventionmmHg (Mean)
Salsalate1.00
Carvedilol-1.50
Placebo2.22

[back to top]

Number of Participants Experiencing Adverse Events Incidence With of Salicylate + Venetoclax + Decitabine

Study drug associated adverse events during therapy (NCT04146038)
Timeframe: During the first 2 cycles, 56 days total

InterventionParticipants (Count of Participants)
Treatment (Salsalate, Decitabine, Azacitidine, Venetoclax)1

[back to top]

Number of Participants With Complete or Partial Response

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT04146038)
Timeframe: During the first 2 cycles 56 days total

InterventionParticipants (Count of Participants)
Treatment (Salsalate, Decitabine, Azacitidine, Venetoclax)1

[back to top]